Loading organizations...

§ Private Profile · San Francisco, CA, USA
Building the frontier of AI driven discovery
δ Thesis has raised $8.4M across 1 funding round.
Key people at δ Thesis.
δ Thesis was founded in 2025 by Luigi Charles (Founder) and Gil Kornberg (Founder) and Sergio Charles (Founder/CEO).
δ Thesis has raised $8.4M in total across 1 funding round.
Thesis is an applied research lab, accelerating AI R&D. Our aim is to help researchers uncover the next Transformer or build the next AlphaFold, faster, more systematically, and at scale. We treat discovery not as a matter of luck, but as an engineering challenge to be solved. The mission is to democratize invention by empowering researchers everywhere with machine intelligence to drive the discovery of the next big thing in AI.
Key people at δ Thesis.
δ Thesis has raised $8.4M across 1 funding round. Most recently, it raised $8.4M Thesis - Series A in May 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 2, 2023 | $8.4M Series A | — | Kate Bock, Kevin Love, Alive Israel Healthtech Fund, Break Trail Ventures, MBX Capital, Redo Ventures, Trust Ventures, Rachel Harris | Announced |
δ Thesis is an investment firm focused on pioneering the frontier of AI-driven discovery, particularly in sectors where artificial intelligence can accelerate innovation and transform traditional R&D processes. Its mission centers on empowering startups that leverage AI to unlock breakthroughs in complex scientific and industrial domains, such as healthcare, life sciences, and advanced software infrastructure. The firm’s investment philosophy emphasizes backing visionary founders who integrate cutting-edge AI technologies to solve high-impact problems, often in early-stage ventures that blend deep domain expertise with AI capabilities.
Key sectors for δ Thesis include AI-powered drug discovery, protein engineering, autonomous industrial AI, and developer infrastructure for AI applications. By investing in these areas, δ Thesis significantly influences the startup ecosystem by catalyzing the growth of companies that reduce innovation cycles, improve precision in scientific research, and enable new AI-driven workflows. This impact fosters a vibrant ecosystem where AI accelerates discovery and commercialization, creating value for both investors and society.
Founded recently in the early 2020s, δ Thesis emerged from a convergence of expertise in AI research, venture capital, and domain-specific sciences such as biotechnology and software engineering. The founding partners bring backgrounds in AI innovation, deep tech investing, and operational scaling of startups. The firm evolved from a traditional tech investment focus to a specialized thesis-driven approach that targets AI as a transformative force in discovery and innovation.
The idea for δ Thesis originated from recognizing the exponential potential of AI to disrupt long-standing R&D bottlenecks, especially in drug discovery and complex engineering. Early investments in startups like those developing AI-driven molecular design platforms and autonomous engineering tools validated the firm’s focus and helped establish its reputation as a frontier AI investor.
δ Thesis rides the wave of AI’s transformative impact on scientific discovery and industrial innovation. The timing is critical as advances in generative AI, machine learning, and autonomous systems converge with increasing data availability and computational power. Market forces such as rising R&D costs, demand for faster drug development, and the need for AI-native infrastructure create fertile ground for δ Thesis’s portfolio companies.
By backing startups that integrate AI deeply into discovery workflows, δ Thesis influences the broader ecosystem by accelerating the adoption of AI in traditionally slow-moving sectors. This catalyzes new business models, shortens innovation cycles, and expands the frontier of what AI can achieve beyond conventional software applications.
Looking ahead, δ Thesis is poised to deepen its focus on next-generation AI platforms that combine generative models, autonomous experimentation, and real-time data integration. Trends such as AI-driven protein engineering, autonomous industrial AI agents, and AI-powered developer tools will shape its investment trajectory. The firm’s influence is likely to grow as it helps define standards for AI-driven discovery and fosters collaborations between AI startups and established industry leaders.
In sum, δ Thesis stands at the vanguard of a paradigm shift where AI is not just a tool but a core driver of innovation, enabling startups to solve some of the most complex scientific and industrial challenges of our time.
δ Thesis was founded in 2025 by Luigi Charles (Founder) and Gil Kornberg (Founder) and Sergio Charles (Founder/CEO).
δ Thesis has raised $8.4M in total across 1 funding round.
δ Thesis's investors include Kate Bock, Kevin Love, ALIVE Israel HealthTech Fund, Break Trail Ventures, MBX Capital, Redo Ventures, Trust Ventures, Rachel Harris.